Eric J Niesor

Summary

Affiliation: F. Hoffmann-La Roche Ltd

Publications

  1. pmc Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport
    Eric J Niesor
    Pharmaceuticals Division, F Hoffmann La Roche Ltd, Basel, Switzerland
    J Lipid Res 51:3443-54. 2010
  2. ncbi Xanthophylls, phytosterols and pre-β1-HDL are differentially affected by fenofibrate and niacin HDL-raising in a cross-over study
    Eric J Niesor
    Pharma Research and Early Development, Pharmaceuticals Division, F Hoffmann La Roche Ltd, Metabolic DBA, Bldg 70 411 Grenzacherstrasse 124, 4070, Basel, Switzerland
    Lipids 48:1185-96. 2013
  3. ncbi Lipid and apoprotein composition of HDL in partial or complete CETP deficiency
    Eric J Niesor
    Pharmaceuticals Division, F Hoffmann La Roche Ltd, Metabolic DBA, Grenzacherstrasse 124, Basel, Switzerland
    Curr Vasc Pharmacol 10:422-31. 2012
  4. doi Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects
    Eric J Niesor
    Discovery Research Metabolic Disease, F Hoffmann La Roche Ltd, Basel, Switzerland
    Atherosclerosis 219:761-7. 2011
  5. doi Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism
    Eric J Niesor
    Pharmaceuticals Division, F Hoffmann La Roche Ltd, Basel, Switzerland
    Curr Opin Lipidol 22:288-95. 2011
  6. doi Evidence for a role of CETP in HDL remodeling and cholesterol efflux: role of cysteine 13 of CETP
    Cyrille Maugeais
    F Hoffmann La Roche Ltd, Pharma Research and Early Development, DTA Cardiovascular and Metabolism, CH 4070, Basel, Switzerland
    Biochim Biophys Acta 1831:1644-50. 2013
  7. pmc Multidimensional profiling of plasma lipoproteins by size exclusion chromatography followed by reverse-phase protein arrays
    Gregor Dernick
    Discovery Technologies, F Hoffmann La Roche, Ltd, Basel, Switzerland
    J Lipid Res 52:2323-31. 2011
  8. ncbi Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels
    Roger G Clerc
    F Hoffmann La Roche Ltd, Basel, Switzerland
    J Hypertens 28:1676-86. 2010
  9. doi MARCO, a macrophage scavenger receptor highly expressed in rodents, mediates dalcetrapib-induced uptake of lipids by rat and mouse macrophages
    Anne Perez
    F Hoffmann La Roche Ltd, Grenzacherstrasse 124, CH 4070 Basel, Switzerland
    Toxicol In Vitro 24:745-50. 2010

Collaborators

Detail Information

Publications9

  1. pmc Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport
    Eric J Niesor
    Pharmaceuticals Division, F Hoffmann La Roche Ltd, Basel, Switzerland
    J Lipid Res 51:3443-54. 2010
    ..These data suggest that modulation of CETP activity by dalcetrapib does not inhibit CETP-induced pre-β-HDL formation, which may be required to increase reverse cholesterol transport...
  2. ncbi Xanthophylls, phytosterols and pre-β1-HDL are differentially affected by fenofibrate and niacin HDL-raising in a cross-over study
    Eric J Niesor
    Pharma Research and Early Development, Pharmaceuticals Division, F Hoffmann La Roche Ltd, Metabolic DBA, Bldg 70 411 Grenzacherstrasse 124, 4070, Basel, Switzerland
    Lipids 48:1185-96. 2013
    ..In addition, the in vitro investigations suggest an important role of plasma apoA-II in xanthophyll metabolism...
  3. ncbi Lipid and apoprotein composition of HDL in partial or complete CETP deficiency
    Eric J Niesor
    Pharmaceuticals Division, F Hoffmann La Roche Ltd, Metabolic DBA, Grenzacherstrasse 124, Basel, Switzerland
    Curr Vasc Pharmacol 10:422-31. 2012
    ..This is only limited by the availability of antibodies against specific apolipoproteins to be investigated...
  4. doi Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects
    Eric J Niesor
    Discovery Research Metabolic Disease, F Hoffmann La Roche Ltd, Basel, Switzerland
    Atherosclerosis 219:761-7. 2011
    ..We evaluated the effect of dalcetrapib, a cholesteryl ester transfer protein modulator, on markers of cholesterol homeostasis in healthy subjects...
  5. doi Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism
    Eric J Niesor
    Pharmaceuticals Division, F Hoffmann La Roche Ltd, Basel, Switzerland
    Curr Opin Lipidol 22:288-95. 2011
    ....
  6. doi Evidence for a role of CETP in HDL remodeling and cholesterol efflux: role of cysteine 13 of CETP
    Cyrille Maugeais
    F Hoffmann La Roche Ltd, Pharma Research and Early Development, DTA Cardiovascular and Metabolism, CH 4070, Basel, Switzerland
    Biochim Biophys Acta 1831:1644-50. 2013
    ..e., cholesteryl ester transfer and HDL remodeling can be uncoupled by interaction of thiol-containing compounds with cysteine 13 of CETP or by introducing large amino acid residues in place of cysteine 13. ..
  7. pmc Multidimensional profiling of plasma lipoproteins by size exclusion chromatography followed by reverse-phase protein arrays
    Gregor Dernick
    Discovery Technologies, F Hoffmann La Roche, Ltd, Basel, Switzerland
    J Lipid Res 52:2323-31. 2011
    ..This finding was elucidated using this technique...
  8. ncbi Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels
    Roger G Clerc
    F Hoffmann La Roche Ltd, Basel, Switzerland
    J Hypertens 28:1676-86. 2010
    ..The increased mortality observed with the cholesteryl ester transfer protein inhibitor torcetrapib is partly due to increased aldosterone production and blood pressure. The mechanisms underlying these effects were investigated...
  9. doi MARCO, a macrophage scavenger receptor highly expressed in rodents, mediates dalcetrapib-induced uptake of lipids by rat and mouse macrophages
    Anne Perez
    F Hoffmann La Roche Ltd, Grenzacherstrasse 124, CH 4070 Basel, Switzerland
    Toxicol In Vitro 24:745-50. 2010
    ..MARCO was expressed at very low levels in human macrophages and was not inducible by LPS. The MARCO receptor may account for the variable species susceptibility towards dalcetrapib-mediated chylomicron uptake by macrophages...